Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REGN 1908 1909

Drug Profile

REGN 1908 1909

Alternative Names: REGN-1908-1909

Latest Information Update: 07 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Developer Regeneron Pharmaceuticals
  • Class Allergy immunotherapies; Antiallergics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Allergic rhinitis
  • Discontinued Hypersensitivity

Most Recent Events

  • 25 Jun 2023 Phase-III clinical trials in Allergic rhinitis (In adults, In children, In adolescents) in US, Belgium, Poland, Germany, France, Canada (SC) (NCT04981717) (EudraCT2021-002089-42)
  • 24 Feb 2023 Updated efficacy data from a phase II trial in Hypersensitivity presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology(AAAAI-2023)
  • 06 Feb 2023 Discontinued - Phase-I/II for Hypersensitivity in United Kingdom, Sweden, New Zealand, Netherlands (SC) prior to February 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top